A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis (AD)

In brief

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Key facts

Study ID
NCT07105488
Run by
Bluefin Biomedicine, Inc.
People needed
225
Starts
2025-07-15
Expected to finish
2027-03-31
Last updated by the study team
2026-07-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.